Gene editing, gene therapy and tissue engineering are emerging regenerative biotherapies that are on the cusp of transforming medical care. RegenBio Summit: Transforming Next-Gen Biotherapeutics 2024, will focus on accelerating technologies from concept to reality for patients in need of new healing options. Register now to join physicians, scientists, general healthcare staff, industry leaders and students from Dec. 9 to 11 at the Ponte Vedra Inn & Club in Ponte Vedra Beach, Florida.

Regenerative biotherapies are made from human sources such as blood, cells and tissues, and have shown potential for targeted healing with relatively few side effects.

"Mayo Clinic is a leader in biomanufacturing clinical-grade regenerative therapies, and advancing them to early-stage clinical trials, and ultimately to clinical care," says Saranya Wyles, M.D., Ph.D., a dermatologist and associate director for education in Mayo Clinic's Center for Regenerative Biotherapeutics. "Our goal is to establish clinical validity and clinical utility of the regenerative medicine model of care for data-driven and trusted practice adoption of biotherapies."

Mayo Clinic's Center for Regenerative Biotherapeutics is sponsoring the RegenBio Summit as part of its objectives of advancing the practice, training the future workforce and biomanufacturing new, lifesaving medicines for phase 1 and 2 clinical trials.

Three keynote speakers for RegenBio Summit

Regenerative biotherapeutics are expected to make up at least 10% of all healthcare in the coming years, as the focus of healthcare shifts from treating disease to rebuilding health.

Three keynote speakers will share their insights on developing regenerative biotherapeutics, how to best navigate the regulatory process and how to safely deliver validated cell and gene therapies to patients.

Peter Marks, M.D., Ph.D., director of the Center for Biologics Evaluation and Research at the Food and Drug Administration (FDA), will talk about regulatory programs to accelerate cell and gene therapies toward FDA approval and the FDA's commitment to approving safe and effective products that address unmet patient needs.

M. Peter Marinkovic, M.D., associate professor of dermatology, Stanford University, will speak about his pioneering research in an FDA-approved topical gene therapy for autoimmune blistering diseases.

Birgit Schultes, Ph.D., senior vice president, Intellia Therapeutics Inc., will discuss preclinical research using the CRISPR Cas-9 gene editing tool to generate cell therapies for cancer and autoimmune diseases.

New sessions will be added to the agenda as the conference planning continues.

Watch the summit website for announcements on plenaries and fireside chats.

Attendees may earn 10.25 continuing medical education credits. They will also have the opportunity to attend keynote presentations, breakout sessions, networking and poster presentations. The symposium is open to those who are interested in regenerative biotherapeutics research, clinical care and workforce development.

###

Related articles:

Save the date! RegenBio Summit: Transforming next-gen biotherapeutics 2024

Science Saturday: Orthobiologics can be nature's healing agents

Related Articles